ERYtech Pharma Announces Positive DSMB Review Of Its Phase 2b Study In Acute Myeloid Leukemia

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ERYTECH Pharma (Paris:ERYP) (NYSE Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that an independent Data and Safety Monitoring Board (DSMB) completed its first assessment of the company’s Phase IIb study in Acute Myeloid Leukemia (AML) study and unanimously recommended continuation of the trial without modification.

Help employers find you! Check out all the jobs and post your resume.

Back to news